Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer

Background Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been recognised as standard treatments in metastatic colorectal cancer (mCRC), the best option remains unclear. Pretreatment tumour growth rate (TGR) is associated with radiotherapeutic efficacy in laryngeal cancer. Howe...

Full description

Bibliographic Details
Main Authors: Toshiki Masuishi, Hiroya Taniguchi, Yoshito Komatsu, Takeshi Kawakami, Yasuyuki Kawamoto, Shigenori Kadowaki, Yusuke Onozawa, Tetsuhito Muranaka, Masahiro Tajika, Hirofumi Yasui, Hiroshi Nakatsumi, Satoshi Yuki, Kei Muro, Katsuhiro Omae, Kentaro Yamazaki
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/4/6/e000584.full

Internet

https://esmoopen.bmj.com/content/4/6/e000584.full

Similar Items